Stockholm, Sweden — number of people living together type 1 diabetes New modeling data suggests that global infections are expected to double by 2040, with most new infections among adults living in low- and middle-income countries.
Predictions developed from available data collected in newly established open source type 1 diabetes index, It provides estimates of type 1 diabetes prevalence, incidence, associated mortality and life expectancy for 201 countries in 2021.
The model also predicts prevalence estimates for 2040. It is the first of his type 1 diabetes data sets to account for the lack of prevalence of premature death, especially in low- and middle-income countries.
“The global prevalence of type 1 diabetes is substantial and increasing. Improved surveillance, especially among adults, who make up the majority of the population with type 1 diabetes, will enable improved care and outcomes.” We have the opportunity to help millions of people live in the decades to come by raising standards of care (including ensuring universal access to healthcare). insulin and other necessities), raising awareness of the signs and symptoms of type 1 diabetes will enable 100% diagnosis rates in all countries,” the authors wrote.
“This study underscores the need for early diagnosis of type 1 diabetes and timely access to quality care,” Dr. Chantal Mathieu said at the European Diabetes Society (EASD) 2022 Annual Meeting. said.
1 in 5 deaths from type 1 diabetes under 25
new discoveries are It was published of The Lancet Diabetes and Endocrinology By Gabriel A. Gregory, M.D., Ph.D., Life for a Child Program, New South Wales, Australia, et al.of T1D index project database Published on September 21, 2022.
According to this model, about 8.4 million people will have type 1 diabetes in 2021, one-fifth of whom will come from low- and middle-income countries. Additionally, he had 3.7 million premature deaths, and had he lived, he would have added to that number. It is estimated that one in five of all deaths from her type 1 diabetes in 2021 will be because she died before the age of 25 because she was undiagnosed.
“It is unacceptable that approximately 35,000 people worldwide will die in 2022 without being diagnosed within one year of symptom onset, and there continue to be wide disparities in life expectancy for people with type 1 diabetes. It hits people in the poorest countries hardest, said Mathieu, senior vice president of EASD and an endocrinologist based in KU Leuven, Belgium.
The model predicts that 13.5 to 17.4 million people will be living with this condition by 2040, with the largest relative increases from 2021 in low- and lower-middle-income countries. Adults account for the majority of type 1 diabetes onset and prevalence, and of the 510,000 new diagnoses worldwide in 2021, he estimates 62% will be in people aged 20 and over. It has been.
Type 1 diabetes is not primarily a childhood disease
Mathieu also noted that the data challenge long-standing views that type 1 diabetes is primarily a childhood condition. In fact, the median age of her type 1 diabetic worldwide he is 37 years old.
“Type 1 diabetes is often referred to as ‘childhood-onset’ diabetes, but this important study found that only 1 in 5 people living with the condition are under the age of 20, and 2/3 are under 20.” to 64 years old, and 1 in 5 is over 65. ”
“This condition does not end at 18. Children become adults and adults grow old. All countries are considering diagnostic and care pathways for people of all ages with type 1 diabetes. needs to be strengthened,” emphasized Matthew.
and, accompanying editorial, Serena Jingchuan Guo (MD, PhD) and Hui Shao (MD, PhD) point out that most studies estimating the burden of diabetes focus on: type 2 diabetes“Type 1 diabetes faces the challenge of being misdiagnosed, underdiagnosed, at high risk of complications and premature death.”
The issue of insulin affordability is a central one, points out Guo and Shao of the Center for Drug Evaluation and Safety, Division of Drug Evaluation and Policy, University of Florida School of Pharmacy, Gainesville.
“Countries need to strengthen insulin price controls and reimbursement policies while ensuring access to insulin and building subsidy programs to meet the growing demand for insulin. Alternative treatment options (e.g., biosimilar products) will also improve the current situation, while optimizing the insulin supply chain between patients,” they conclude.
This research was funded by JDRF, of which four co-authors are employees.Editor No related financial relationships have been reported.
Lancet diabetic endocrinol. Published online on September 13, 2022. Overview, editorial
Miriam E. Tucker is a freelance journalist based in Washington, DC. She is a regular contributor to her Medscape, and her other work appears in her The Washington Post, her Shots blog on NPR, and Diabetes Forecast magazine. She uses @MiriamETucker on her Twitter.
Follow us for diabetes and endocrinology news twitter When Facebook.
